Furthermore, cytokine inhibitors, such as TNF-α blockers (adalimumab, infliximab), IL-6 antagonists (tocilizumab), and IL-1β inhibitors (canakinumab), are being actively explored for their potential to reduce chronic inflammation in retinal diseases. The gene discussed is IL1B; the disease is Abnormal retinal morphology.